Epigenetics in Alzheimer's Disease

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2022 Jul 11

PMID 35813941

Authors

Xiaodie Gao

Qiang Chen

Hua Yao

Jie Tan

Zheng Liu

Yan Zhou

Zhenyou Zou

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease with unknown pathogenesis and complex pathological manifestations. At present, a large number of studies on targeted drugs for the typical pathological phenomenon of AD (Aβ) have ended in failure. Although there are some drugs on the market that indirectly act on AD, their efficacy is very low and the side effects are substantial, so there is an urgent need to develop a new strategy for the treatment of AD. An increasing number of studies have confirmed epigenetic changes in AD. Although it is not clear whether these epigenetic changes are the cause or result of AD, they provide a new avenue of treatment for medical researchers worldwide. This article summarizes various epigenetic changes in AD, including DNA methylation, histone modification and miRNA, and concludes that epigenetics has great potential as a new target for the treatment of AD.

Citing Articles

Epigenetic regulation of iron metabolism and ferroptosis in Parkinson's disease: Identifying novel epigenetic targets.

Gao X, Ding J, Xie J, Xu H Acta Pharmacol Sin. 2025; .

PMID: 40069488 DOI: 10.1038/s41401-025-01499-6.

Interaction of genetic variants and methylation in transcript-level expression regulation in Alzheimer's disease by multi-omics data analysis.

Han S, Cho S, Choi W, Eilbeck K, Coon H, Nho K BMC Genomics. 2025; 26(1):170.

PMID: 39979805 PMC: 11844006. DOI: 10.1186/s12864-025-11362-x.

Integrating epigenetic modification and stem cell therapy strategies: A novel approach for advancing Alzheimer's disease treatment - A literature review.

Widaja E, Pawitan J Narra J. 2025; 4(3):e935.

PMID: 39816083 PMC: 11731673. DOI: 10.52225/narra.v4i3.202.

Therapeutic Options in Alzheimer's Disease: From Classic Acetylcholinesterase Inhibitors to Multi-Target Drugs with Pleiotropic Activity.

Cacabelos R, Martinez-Iglesias O, Cacabelos N, Carrera I, Corzo L, Naidoo V Life (Basel). 2025; 14(12.

PMID: 39768263 PMC: 11678002. DOI: 10.3390/life14121555.

Whole genome methylation sequencing in blood from persons with mild cognitive impairment and dementia due to Alzheimer's disease identifies cognitive status.

Madrid A, Papale L, Bergmann P, Breen C, Clark L, Asthana S Alzheimers Dement. 2025; 21(2):e14474.

PMID: 39743828 PMC: 11848161. DOI: 10.1002/alz.14474.

References

Price A, Collado-Torres L, Ivanov N, Xia W, Burke E, Shin J . Divergent neuronal DNA methylation patterns across human cortical development reveal critical periods and a unique role of CpH methylation. Genome Biol. 2019; 20(1):196. PMC: 6761727. DOI: 10.1186/s13059-019-1805-1. View

Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai L . Recovery of learning and memory is associated with chromatin remodelling. Nature. 2007; 447(7141):178-82. DOI: 10.1038/nature05772. View

Kouzarides T . Chromatin modifications and their function. Cell. 2007; 128(4):693-705. DOI: 10.1016/j.cell.2007.02.005. View

Barbato C, Canu N, Zambrano N, Serafino A, Minopoli G, Ciotti M . Interaction of Tau with Fe65 links tau to APP. Neurobiol Dis. 2005; 18(2):399-408. DOI: 10.1016/j.nbd.2004.10.011. View

Neelamegam R, Ricq E, Malvaez M, Patnaik D, Norton S, Carlin S . Brain-penetrant LSD1 inhibitors can block memory consolidation. ACS Chem Neurosci. 2012; 3(2):120-128. PMC: 3382965. DOI: 10.1021/cn200104y. View

Mellen M, Ayata P, Dewell S, Kriaucionis S, Heintz N . MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell. 2012; 151(7):1417-30. PMC: 3653293. DOI: 10.1016/j.cell.2012.11.022. View

Dabin L, Guntoro F, Campbell T, Belicard T, Smith A, Smith R . Altered DNA methylation profiles in blood from patients with sporadic Creutzfeldt-Jakob disease. Acta Neuropathol. 2020; 140(6):863-879. PMC: 7666287. DOI: 10.1007/s00401-020-02224-9. View

Faghihi M, Modarresi F, Khalil A, Wood D, Sahagan B, Morgan T . Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med. 2008; 14(7):723-30. PMC: 2826895. DOI: 10.1038/nm1784. View

Horvath S, Raj K . DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet. 2018; 19(6):371-384. DOI: 10.1038/s41576-018-0004-3. View

10.

Flamier A, El Hajjar J, Adjaye J, Fernandes K, Abdouh M, Bernier G . Modeling Late-Onset Sporadic Alzheimer's Disease through BMI1 Deficiency. Cell Rep. 2018; 23(9):2653-2666. DOI: 10.1016/j.celrep.2018.04.097. View

11.

Man S, Karki R, Kanneganti T . Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. Immunol Rev. 2017; 277(1):61-75. PMC: 5416822. DOI: 10.1111/imr.12534. View

12.

Miner S, Evrovski J, Cole D . Clinical chemistry and molecular biology of homocysteine metabolism: an update. Clin Biochem. 1997; 30(3):189-201. DOI: 10.1016/s0009-9120(96)00172-5. View

13.

Szwagierczak A, Bultmann S, Schmidt C, Spada F, Leonhardt H . Sensitive enzymatic quantification of 5-hydroxymethylcytosine in genomic DNA. Nucleic Acids Res. 2010; 38(19):e181. PMC: 2965258. DOI: 10.1093/nar/gkq684. View

14.

Borchelt D, Thinakaran G, Eckman C, Lee M, Davenport F, Ratovitsky T . Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron. 1996; 17(5):1005-13. DOI: 10.1016/s0896-6273(00)80230-5. View

15.

Chen Y, Li Z, Chen X, Zhang S . Long non-coding RNAs: From disease code to drug role. Acta Pharm Sin B. 2021; 11(2):340-354. PMC: 7893121. DOI: 10.1016/j.apsb.2020.10.001. View

16.

Do Carmo S, Hanzel C, Jacobs M, Machnes Z, Iulita M, Yang J . Rescue of Early bace-1 and Global DNA Demethylation by S-Adenosylmethionine Reduces Amyloid Pathology and Improves Cognition in an Alzheimer's Model. Sci Rep. 2016; 6:34051. PMC: 5041108. DOI: 10.1038/srep34051. View

17.

Hanisch U, Kettenmann H . Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007; 10(11):1387-94. DOI: 10.1038/nn1997. View

18.

Semick S, Bharadwaj R, Collado-Torres L, Tao R, Shin J, Deep-Soboslay A . Integrated DNA methylation and gene expression profiling across multiple brain regions implicate novel genes in Alzheimer's disease. Acta Neuropathol. 2019; 137(4):557-569. DOI: 10.1007/s00401-019-01966-5. View

19.

Wood H . Alzheimer disease: AD-susceptible brain regions exhibit altered DNA methylation. Nat Rev Neurol. 2014; 10(10):548. DOI: 10.1038/nrneurol.2014.164. View

20.

Li L, Qiu Y, Miao M, Liu Z, Li W, Zhu Y . Reduction of Tet2 exacerbates early stage Alzheimer's pathology and cognitive impairments in 2×Tg-AD mice. Hum Mol Genet. 2020; 29(11):1833-1852. DOI: 10.1093/hmg/ddz282. View